Hydropothecary (THCX) PT Raised to C$9.50

Hydropothecary (CVE:THCX) had its price objective increased by Beacon Securities from C$8.50 to C$9.50 in a report issued on Thursday. The firm currently has a buy rating on the stock.

Separately, Canaccord Genuity increased their target price on shares of Hydropothecary from C$5.25 to C$5.75 in a research report on Thursday, February 15th.

How to Become a New Pot Stock Millionaire

Shares of THCX opened at C$4.27 on Thursday. Hydropothecary has a 52 week low of C$1.10 and a 52 week high of C$5.25.

In other Hydropothecary news, insider Sebastien G. St-Louis sold 120,000 shares of the stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of C$3.87, for a total transaction of C$464,400.00. Also, insider Sebastien G. St-Louis sold 84,000 shares of the stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of C$3.66, for a total transaction of C$307,440.00. In the last 90 days, insiders have sold 477,334 shares of company stock worth $1,837,909.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/04/16/hydropothecary-thcx-pt-raised-to-c9-50.html.

Hydropothecary Company Profile

The Hydropothecary Corporation, together with its subsidiaries, produces and distributes medical marijuana products. The company is headquartered in Gatineau, Canada.

Receive News & Ratings for Hydropothecary Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hydropothecary and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply